Colorado ranks among the 20 best places for the biotechnology industry, according to Genome Technology magazine, a speciality print and online publication for molecular biology scientists, professionals and engineers.
The publication listed the Denver-Boulder area as one of nine emerging biotechnology regions along with Alabama, New York, Tennessee, Texas, the St. Louis-Kansas City area; Oslo, Norway; China and India. The 11 established regions included Boston, San Diego, San Francisco, Washington, D.C., Research Triangle, N.C., Florida, New Jersey, Pennsylvania, Wisconsin, Ontario, Canada and Singapore.
The Denver-Boulder area was selected, Genome Technology said in its June issue, because of its 10,000 biotechnology workers, a $150 million expansion planned by Amgen Inc. in Boulder and the recent conversion of the former Fitzsimmons Army Medical Center to a bioscience business park that includes the University of Colorado Health Sciences Center, Children’s Hospital and a biotechnology incubator.
Colorado also scored a fourth-place ranking from Families USA’s Global Health Initiative among states generating the most economic activity per dollar of funding from the National Institutes of Health. Colorado generated $787 million in business activity from $336 million in NIH funding, or $2.34 for each dollar of funding from the agency, which ranked the state behind Texas, California and Georgia.
The Milken Institute’s State Technology and Science Index ranked Colorado third after Massachusetts and Maryland, based on 77 indicators ranging from research and development, risk capital, entrepreneurial infrastructure to human capital investment, technology and science work force and technology concentration and dynamism. Colorado previously was ranked third in 2004 and second in 2002 by the institute.